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Liver fibrosis is a consequence of chronic liver dis-
eases and thus a major cause of mortality and
morbidity. Clinical evidence and animal studies sug-
gest that local tissue homeostasis is disturbed due to
immunological responses to chronic hepatocellular
stress. Poorly defined stress-associated inflam-
matory networks are thought to mediate gradual
accumulation of extracellular-matrix components,
ultimately leading to fibrosis and liver failure. Here
we have reported that hepatic expression of inter-
leukin-33 (IL-33) was both required and sufficient
for severe hepatic fibrosis in vivo. We have demon-
strated that IL-33’s profibrotic effects related to
activation and expansion of liver resident innate
lymphoid cells (ILC2). We identified ILC2-derived
IL-13, acting through type-II IL-4 receptor-depen-
dent signaling via the transcription factor STAT6
and hepatic stellate-cell activation, as a critical
downstream cytokine of IL-33-dependent pathologic
tissue remodeling and fibrosis. Our data reveal key
immunological networks implicated in hepatic
fibrosis and support the concept of modulation of
IL-33 bioactivity for therapeutic purposes.
INTRODUCTION
Liver fibrosis—a widespread consequence of chronic liver
diseases that encompass infection-related hepatic fibrosis
(e.g., hepatitis C virus infections, Schistosomiasis) metabolic-
type fibrosis (e.g., steatohepatitis), and biliary-type fibrosis
(e.g., primary sclerosing cholangitis)—is amajor cause ofmortal-
ity and morbidity. It develops as a result of chronic inflammatory
responses to persistent hepatocellular stress, which finally cul-
minates in pathologic tissue remodeling and increased deposits
of extracellular matrix (ECM) proteins (Bataller and Brenner,
2005). Later stages of progressive liver fibrosis are characterized
by fundamental changes in liver architecture, which predispose
to organ failure and hepatocellular carcinomas.Hepatic stellate cells (HSCs) are viewed as a predominant
cellular source of ECM components during fibrosis. Injury-asso-
ciated immunological processes supporting transdifferentiation
of quiescent HSC into fibrogenic myofibroblasts in the course
of liver injury were shown to be particularly important for fibrosis
(Friedman, 2010). The inflammatory response associated with
liver injury and fibrosis is a dynamic process that involves
intrahepatic accumulation of immune cell subsets. Those are
attracted to and activated in the liver by specific patterns of che-
mokines and cytokines produced by liver-resident cells. Chemo-
kines and cytokines like transforming growth factor-b (TGF-b),
IL-6, PDGF, and IL-1 have been implicated in HSC function
in vitro and in vivo (Seki et al., 2009; Wasmuth et al., 2010;
Weiler-Normann et al., 2007). However, many of the early events
in liver fibrosis, including the exact nature of infiltrating patho-
genic immune cell subsets and key molecular mediators, which
support local inflammation and activation of HSC remain unde-
fined (Friedman, 2008).
Recently, interleukin-33 (IL-33), an IL-1-related cytokine, has
been implicated in inflammatory conditions in animal models
(Haraldsen et al., 2009; Schmitz et al., 2005; Xu et al., 2008). In
addition, IL-33 has been suggested to possess profibrotic prop-
erties in skin and lung (Rankin et al., 2010; Yanaba et al., 2011).
IL-33 might be actively secreted from cells by yet-undefined
pathways, but passive release from necrotic cells is reported
to be a dominant mechanism for abundance of extracellular IL-
33 in vivo (Cayrol and Girard, 2009; Lu¨thi et al., 2009). Therefore,
it is proposed that IL-33might be considered as a damage-asso-
ciated molecular pattern (DAMP) that contributes to tissue injury
responses as well as inflammatory responses (Palmer and
Gabay, 2011). Cytokine-like activity of extracellular IL-33 is
mediated through a heteromeric cell-surface receptor consisting
of the ubiquitous IL-1R associated protein (IL-1R3) and the more
selectively expressed IL-33 receptor (ST2, IL-1R4) (Chackerian
et al., 2007; Palmer et al., 2008). Recently, phenotypically similar
populations of innate lymphoid cells (ILC) that express ST2 and
respond to IL-33 by production of the T helper-2 (Th2) cell-asso-
ciated cytokines IL-4, IL-5, and IL-13 have been described (Moro
et al., 2010; Neill et al., 2010; Price et al., 2010; Saenz et al.,
2010b). Furthermore, these cells (ILC2) have been shown to be
a major in vivo source of IL-9 (Wilhelm et al., 2011) and intrinsic
expressions of the transcription factors RORa and GATA3
have been shown to be important for the generation of at leastImmunity 39, 357–371, August 22, 2013 ª2013 Elsevier Inc. 357
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Figure 1. IL-33 Is Upregulated in Hepatic Fibrosis
(A) Serum IL-33 (n = 11 per group; ***p < 0.001) in healthy controls or cirrhosis patients was determined by ELISA.
(B) Serum IL-33 protein concentrations in control mice or mice with TAA or CCL4 induced liver fibrosis. (n = 5 per group; **p < 0.01; ***p < 0.001) were determined.
(C) Representative images of liver sections fromCCL4, TAA, S.mansoni-infected and control-treatedmice stained for IL-33 by immunohistochemistry. Scale bars
represent 50 mm.
(legend continued on next page)
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IL-33-Dependent ILC2 Mediate Hepatic Fibrosissome of these ILC2 populations (Wong et al., 2012, Hoyler et al.,
2012). In mice and humans, ILC2 are primarily found in lymphoid
tissues associated with barrier surfaces and a critical role of ILC2
and ILC2-derived cytokines has been suggested in the context
of host protection against helminths and viral infections (Chang
et al., 2011; Mjo¨sberg et al., 2011; Monticelli et al., 2011).
Here we have identified IL-33 as key mediator of hepatic
fibrosis in vivo. Our data suggest that IL-33 is released in
response to chronic hepatocellular stress and that extracellular
IL-33, via ST2-dependent signaling, leads to accumulation and
activation of ILC2 in the liver. Activated hepatic ILC2 produce
IL-13, which in turn triggers activation and transdifferentiation
of HSC in an IL-4Ra- and STAT6 transcription-factor-dependent
fashion. These findings characterize molecular and cellular
networks implicated in hepatic fibrosis and highlight the role of
IL-33 at the apex of the profibrotic cascade. In addition, a path-
ogenic capacity of ILC2 in the context of the tissue damage
response is unveiled. Finally, our results validate the idea of
therapeutic modulation of IL-33-dependent networks in hepatic
inflammation and fibrosis.
RESULTS
IL-33 Expression Is Elevated in Hepatic Fibrosis and
IL-33 Is Sufficient to Drive Excess ECM Deposition
in the Liver
Previous studies suggest a role for IL-33 in the context of Th2
cell-associated inflammation and fibrosis of skin and lung
(Palmer and Gabay, 2011; Rankin et al., 2010). To address its
association with development of human fibrotic liver disease,
we evaluated IL-33 serum concentrations in a cohort of patients
with liver cirrhosis. Significantly higher serum amounts of IL-33
were observed in patients compared to controls (Figure 1A). In
rodent models of hepatic fibrosis, chronic hepatocellular stress
is mimicked by repeated application of hepatotoxic chemicals.
Hence, we next evaluated the expression of IL-33 in mice in
which liver fibrosis was experimentally induced in two indepen-
dent models by repeated administration of Thioacetamide
(TAA) or Carbontetrachloride (CCL4). In mice treated with either
chemical, IL-33 serum concentrations were significantly
increased (Figure 1B), and increased hepatic IL-33 protein
expression was demonstrated by immunohistochemical staining
(Figure 1C). Furthermore, hepatic IL-33 protein expression was
strongly increased in amousemodel of chronic Schistosomiasis,
an infection predisposing mice and humans to severe hepatic
inflammation and fibrosis (Figure 1C). In addition, IL-33
messenger RNA (mRNA) expression in the liver was elevated
by TAA and CCl4 treatment (data not shown). No differential
IL-33 expression was found in other tissues of CCL4 or TAA(D) We HD injected 2.5 mg of mcIL-33 expression or control vector (mock) into m
protein, with HE or, for visualization of collagen, with Sirius Red.
(E) IL-33 serum concentrations in mcIL-33 treated mice (***p < 0.001) were determ
Sirius Red).
(F) Total hepatic collagen of indicated mice was quantified by hydroxyproline as
(G) mRNAs of selected fibrosis-associated genes in liver total RNA were quantifie
of at least two different experiments with similar results.
(H) CD1 mice infected with 30 S. mansoni cercaria were HD injected with mcIL-
weights were determined. Hepatic collagen content was determined by hydroxy
sentative of two different experiments with similar results. Error bars indicate SEsubjectedmice suggesting that increased serum IL-33 is unlikely
to originate from nonhepatic cells in these models (data not
shown).
In order to establish whether release of IL-33 from liver cells is
sufficient for induction of fibrosis, we generated a vector encod-
ing a secreted version of IL-33 (mcIL-33) controlled by liver-spe-
cific regulatory elements and took advantage of the technology
of hydrodynamic delivery (HD) for sustained in vivo transduction
of hepatocytes with IL-33 (Liu et al., 1999) (see Figure S1A avail-
able online). Our data confirmed that IL-33 was overexpressed
in hepatocytes of IL-33 vector-injected but not control vector-
injected mice (Figure 1D). Similarly, IL-33 protein was detected
in serum (Figure 1E). Other studies have demonstrated that
rIL-33 can induce systemic expression of IL-13 in vivo (Rankin
et al., 2010; Schmitz et al., 2005). At the IL-33 doses used for
HD in our studies, no serum IL-13 was detectable (data not
shown), suggesting that liver-specific rather than systemic
effects of IL-33 were observed.
Four weeks after HD, IL-33 vector-injected but not control vec-
tor-injected animals showed excessive immune cell infiltrates
and increased hepatic collagen as evident by hematoxylin and
eosin (H&E) and Sirius Red staining, respectively (Figure 1D). A
significant increase in total hepatic collagen was confirmed by
applying the quantitative hydroxyproline assay to harvested liver
tissues (Figure 1F). Treatment with IL-33 also induced gene
expression of fibrogenic markers Acta1, Timp1, andCol1a1 (Fig-
ure 1G). No increase in hepatic collagen was observed upon
injection of the same dose of IL-33 vector into IL-33R (ST2)-defi-
cient mice, confirming that ST2 is required for IL-33-mediated
hepatic fibrosis (Figure S1B).
Moreover, S. mansoni dependent liver damage strongly
increased upon mcIL-33 mediated hepatic IL-33 overexpression
(Figure 1H), and such treated mice display premature death due
to severe disease (data not shown).
To further analyze the functional role of the IL-33 pathway in
hepatic fibrosis in vivo, we expressed biologically active IL-33
in livers of mice. We generated a conditional transgenic line
that allowed tissue- or cell-type-specific overexpression of
IL-33 by Cre recombinase-mediated deletion of an EGFP-Stop
cassette (eGFPSTOPfloxIl33 mice; Figure S1C). We induced
hepatic IL-33 expression in eGFPSTOPfloxIl33 mice by HD of a
Cre-expression plasmid (Figure S1D). Examination of livers of
these mice 4 weeks later revealed that hepatic IL-33 expression
led to profound collagen depositions and fibrosis (Figure S1D).
IL-33 Deficiency Ameliorates Experimental Fibrosis
In Vivo
We next investigated whether IL-33 deficiency affects develop-
ment of hepatic fibrosis in vivo; fibrosis was induced in Il33/ice. Mice were analyzed 4 weeks later. Liver sections were stained for IL-33
ined by ELISA. Scale bars represent 100 mm (IL-33 staining) or 200 mm (HE and
say (n = 9–10 per group: ***p < 0.001).
d by qPCR (n = 9–10 per group; ***p < 0.001; *p < 0.05). Data are representative
33 at week 3 after infection. Three weeks later, mice were sacrificed and organ
proline quantification (n = 5 per group; **p < 0.01; *p < 0.05). Data are repre-
M. See also Figure S1.
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Figure 2. IL-33 Deficiency Ameliorates Experimental Fibrosis In Vivo
Il33/ or C57BL/6 control mice (n = 5 per group) were treated with CCL4 for 4 weeks.
(A) Livers were stained for determination of fibrillar collagen depositions with Sirius Red and hydroxyproline amounts in livers were determined (*p < 0.01).
(B) Timp1 mRNA in liver total RNA of CCL4 treated mice or controls was quantified by qPCR (**p < 0.01).
(legend continued on next page)
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IL-33-Dependent ILC2 Mediate Hepatic Fibrosismice and wild-type (WT) littermates by repeated administration
of CCL4. After 4 weeks, Il33
/ mice displayed a significant
reduction in excess collagen deposits as shown by Sirius Red
staining and hydroxyproline quantification (Figure 2A), whereas
total hepatic collagen was similar in unchallenged Il33/ mice
compared to controls (data not shown). Consistent with the
ameliorated fibrotic phenotype, a strong reduction in mRNA
expression of Timp1, a gene associated with HSC activation
and fibrosis in humans and mice (Benyon et al., 1996; Jin
et al., 2011), was observed in livers of Il33/ mice (Figure 2B).
In addition, a biliary fibrosis model with experimental ligation of
the common bile duct (BDL) was employed. Again, histologic
assessment of liver tissue and total collagen quantification
showed that fibrosis was markedly reduced in Il33/ mice
compared to controls (Figure 2C). Reduction of fibrosis was
further confirmed by qPCR-based quantification of fibrosis-
associated gene expression with liver RNA of mice subjected
to BDL for 16 days. Amounts of Col1a1, Col3a1, and Timp1
were dramatically reduced in livers of Il33/ mice (Figure 2D).
To evaluate whether modulation of IL-33 bioactivity affects liver
pathology in Schistosomiasis, we next treated mice 3 weeks
after infection with a construct for soluble ST2 (sST2), a naturally
occurring IL-33 decoy receptor. Compared to controls, mice
subjected to sST2 delivery developed significantly less liver dis-
ease (Figure 2E), indicating that IL-33 has proinflammatory and/
or profibrotic functions in the context of parasite-induced liver
disease.
Some reports describe IL-33 as intracellular protein that
unfolds its ST2-dependent cytokine activity only after passive
release from damaged cells (Palmer and Gabay, 2011). How-
ever, whether prominent functional roles exist for intracellular
IL-33 appears to be poorly understood at this time. Therefore,
one possible interpretation of our result of reduced hepatic
fibrosis in Il33/mice is that intracellular IL-33 possesses profi-
brotic properties. To address this, we delivered a vector encod-
ing an intracellular expressed version of IL-33, including the
nuclear localization signal, to Il33/ mice via HD. Although
hepatic IL-33 protein expression was evident from IHC staining
(Figure 2F), no IL-33 was detectable in the serum of those ani-
mals (data not shown) and no liver pathology was observed
by histology (Figure 2G). However, when those animals were
treated with CCL4, IL-33 became detectable in the serum (Fig-
ure 2H) and hepatic fibrosis was observed (data not shown).
To obtain further information about molecular networks
involved in the progression of hepatic fibrosis in this model, we
next generated mRNA expression profiles of cytokines, chemo-
kines, and profibrogenic and fibrolytic genes in livers ofmicewith
IL-33 dependent fibrosis by qPCR. Thereby, numerous differen-
tially regulated genes were identified (Table S1) that, when(C and D) Il33/ or C57BL/6 controls underwent BDL surgery. Sixteen days later
Sirius Red and hydroxyproline amounts in livers were quantified (*p < 0.05); (D) m
controls were quantified by qPCR.
(E) CD1 mice were infected with30 S. mansoni cercaria. Three weeks later, mice
receptor. Four weeks later, mice were sacrificed. Collagen deposits in livers of m
Granulomas were counted in ten low-power fields per slide (n = 5 per group; ***p
(F–H) Il33/mice were injected with 5 mg of a liver-specific expression construct f
nuclear IL-33 expression in hepatocytes. (G) Analysis of livers of mice 7 days a
350 mg/kg TAA. Three days later, serum IL-33 concentrations were determine
experiments with similar results. Scale bars represent 200 mm or 50 mm (IL-33 stanalyzed for relationships and biological significance by Ingenu-
ity Pathway Analysis, are clearly implicated in gene expression
networks associated with development of liver fibrosis and
HSC activation (Figure S2).
IL-13-Dependent Type II IL-4 Receptor Signaling
Mediates IL-33-Dependent Fibrosis
Our next objective was to define pathways required for IL-33-
dependent fibrotic liver disease in more detail. Because IL-13
mRNA was most prominently increased in livers of mice with
IL-33 induced fibrosis and IL-33 treated S. mansoni-infected
mice (Figures S3A and S3B), we treated Il13/ mice and WT
littermates with mcIL-33 and examined livers 4 weeks later.
Sirius Red staining and quantification of hepatic collagen re-
vealed that fibrosis in IL-33 treated Il13/ mice was reduced
compared with controls suggesting critical profibrotic roles of
IL-13 in this model (Figure 3A). IL-13 mediates biological func-
tions via the type II IL-4 receptor, which is composed of IL-4Ra
and IL-13Ra1 (Wills-Karp and Finkelman, 2008). To test whether
type II IL-4R signaling is involved in IL-33 dependent fibrosis, we
injected mcIL-33 into Il4Ra/ mice. As demonstrated by Sirius
Red staining and hydroxyproline assay, Il4Ra/mice had a sig-
nificant reduction in fibrosis compared to Il4Ra+/+ mice (Fig-
ure 3B). Furthermore, HD of an IL-13 construct, but not con-
structs for the Th2-related cytokines IL-5 and IL-9 (Figure S4A),
clearly induced ECM depositions in livers of WT mice. In
contrast, Il4Ra/ mice were not susceptible for IL-13 depen-
dent fibrosis (Figure S4A). Staining of liver sections from cirrhosis
patients demonstrated that both IL-4Ra and IL-13Ra1 are
strongly upregulated in diseased areas suggesting that these
mechanistic findings in mice might translate to pathogenesis of
human liver disease (Figure 3C).
IL-13-Dependent Type II IL-4R Signaling Mediates HSC
Activation
Our observation that IL-13 is a dominant effector of the profibro-
genic function of IL-33 prompted us to further investigate the bio-
logical role of IL-13 in hepatic fibrogenesis. Effects of IL-13 on
both immune and nonhematopoietic cells have been described
(Koyasu and Moro, 2011). We therefore assessed whether
IL-4Ra signaling in hematopoietic or nonhematopoietic cells is
required for fibrogenesis by generating chimeras in which IL-
4Ra-deficient or WT bone marrow was transferred into recipient
mice that were pretreated with clodronate-liposomes to deplete
Kupffer cells. However, IL-33 induced a similar degree of hepatic
fibrosis in both chimeric strains (Figure S4B). Because HSCs
have been suggested to be predominant ECM-producers in
the course of fibrosis, we analyzed whether IL-33-dependent
IL-13 production directly regulates these nonimmune cells. We, mice were sacrificed and livers were analyzed. (C) Sections were stained with
RNAs of selected fibrosis-associated genes in liver total RNA of BDL mice or
were HD injected with a liver-specific expression construct for the soluble ST2
ice were determined by Sirius Red staining and hydroxyproline quantification.
< 0.001; *p < 0.05).
or full-length IL-33 (aa 1–260). (F) IL-33-specific immunostaining demonstrating
fter treatment (H) 7 days after HD mice were treated with 1.8 ml/kg CCL4 or
d by ELISA (***p < 0.001). Data are representative of at least two different
aining). Error bars indicate SEM. See also Figure S2 and Table S1.
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Figure 3. IL-13 Dependent Type II IL-4 Receptor Signaling Is Required for IL-33-Mediated Fibrosis and HSC Activation
IL-33 expression constructs were injected into (A) Il13/mice, (B) Il4Ra/mice, or Balb/c controls. Mice were sacrificed 4 weeks later and collagen depositions
in livers were analyzed by Sirius Red staining or hydroxyproline assay (n = 10 mice per group; ***p < 0.001;**p < 0.01). Scale bars represent 200 mm.
(C) Representative pictures of liver tissue sections from healthy controls or patients with liver cirrhosis that were stained for IL-4Ra or IL-13Ra by immunohis-
tochemistry. Scale bars represent 50 mm.
(legend continued on next page)
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IL-33-Dependent ILC2 Mediate Hepatic Fibrosisisolated HSC and found that they produced mRNAs for both
components of the functional type II IL-4R, IL-4Ra, and IL-
13Ra1. In addition, surface expression of IL-13Ra1 was demon-
strated by flow cytometry (Figure S4C). Immunoblot analysis
with liver lysates demonstrated increased STAT6 phosphoryla-
tion after injection of mcIL-33 in vivo (Figure 3D, top panel).
Moreover, purified primary HSC, stimulated with IL-13 ex vivo,
responded by phosphorylation of STAT6, a critical transcription
factor for IL-4- and IL-13-dependent cellular responses (Heben-
streit et al., 2006) (Figure 3D, lower panel). Additionally, stimula-
tion of HSC with IL-13 increased their proliferation in vitro
(Figure 3E) and elicited an IL-13-dependent increase in mRNA
of profibrotic genes (Figure S4D) and chemokines (Figure 3F).
Collectively, these data suggest that IL-33 through IL-13 modu-
lates HSC functions.
ILC2 Are Increased in Livers of Mice with Hepatic
Fibrosis
Different cell types have been described as possible sources of
IL-13 in response to IL-33 stimulation (Besnard et al., 2011;
Kroeger et al., 2009; Stolarski et al., 2010). To identify which cells
are the dominant producers of IL-33-dependent IL-13 in this sys-
tem, we first assessed whether immune cells or liver-resident
cells are critical targets of IL-33 by generating chimeras in which
ST2-deficient orWTBMcells were transferred intoWT recipients
(Figure 4A). Interestingly, mcIL-33 treatment induced different
responses in the two strains: whereas mice reconstituted with
WT BM developed severe fibrotic disease, chimeras with defec-
tive IL-33 signaling in BM-derived cells did not show liver pathol-
ogy or excess collagen (Figures 4B and 4C).
To characterize the role of these IL-33-responsive hematopoi-
etic cells further, we determined the contribution of lymphocytes
for progression of liver fibrosis. Rag1/ mice treated with
mcIL-33 developed marked liver pathology at 4 weeks after
HD (Figure 4D). In fact, Sirius Red staining and hydroxyproline
determination indicated that the extent of fibrosis was more
pronounced in these mice compared to controls (Figures 4D
and 4E). In contrast, Rag1/gc/ mice, which—in addition to
B and T cells—lack gc-dependent lymphocytes, e.g., natural
killer cells and ILC, were resistant to IL-33 mediated hepatic
fibrosis (data not shown). We next did qPCR analysis to compare
the expression of several fibrosis-associated genes in livers from
mcIL-33-treated Rag1/ and WT mice. Indeed, and consistent
with our data described above, hepatic mRNAs for Th2 cell-
associated cytokines, particularly IL-13, were strongly elevated
in Rag1/mice. In contrast, amounts of the antifibrotic cytokine
interferon-g were lower in Rag1/ mice (Figure 4F).
Recently, several reports have described innate lymphoid cell
populations (nuocytes, natural helper cells, innate helper cells,
ILC2) that respond to stimulation with IL-25 and/or IL-33, are
capable of producing substantial amounts of IL-13 and are
important for host responses to infections (Moro et al., 2010;
Neill et al., 2010; Price et al., 2010; Saenz et al., 2010b). Our
observation that IL-33 induced hepatic fibrosis developed inde-(D) Detection of activated STAT6 by immunoblot in whole liver lysates (top pane
(E) HSCs were stimulated in vitro with rIL-13 for 4 days. Cell growth was assesse
(F) HSCs were cultivated for 48 hr with or without the presence of 30 ng/ml IL-13. C
of at least two different experiments. Error bars indicate SEM. See also Figure Spendently of adaptive immune cells and largely depended on IL-
13, but not on the presence of basophils and mast cells (Figures
S5A and S5B), prompted us to analyze the functional role of ILC2
in fibrotic liver disease. First, we treated Il4-eGFP (4get) mice, a
reporter strain marking type-2 competent cells by expression of
eGFP (Mohrs et al., 2001), with mcIL-33 and analyzed eGFP
expression in isolated liver cells by flow cytometry (Figure 5A).
As a result, the number of eGFP+Sca-1+ cells increased dramat-
ically with IL-33 treatment. Sca-1 is expressed on hematopoietic
progenitors and was previously shown to be expressed by ILC2
(Saenz et al., 2010a). In further experiments, we were able to
recover small numbers of lin, CD45+ cells, characterized
by expression of IL-33R, IL-7Ra, CD44, CD90.2, ICOS, and
Sca-1, resembling ILC2, from the livers of naive mice. In livers
of mcIL-33-treated mice, we found these cells strongly enriched
(Figure 5B), and moreover, these ILC2 produced IL-13 as shown
by intracellular flow cytometry analysis (Figure 5C). Recently, the
transcription factor RORa has been shown to be critical for nuo-
cyte development (Wong et al., 2012), and mice treated with
mcIL-33 had increased liver RORamRNA expression compared
to controls (Figure 5D). To determine a potential impact of RORa
on the development of liver ILC2, we analyzed RORa expression
in purified liver ILC2. Quantitative analysis of RORa mRNA
showed high RORa abundance in ILC2 compared to ROR-gt, a
factor involved in the developmental program of other ILC
lineages (ILC3) (Figure 5E). In addition, hepatic numbers of
linSca-1+ICOS+ cells were reduced in chimeric mice reconsti-
tuted with BM from mice lacking RORa, suggesting that liver
ILC2 are developmentally related to ILC2 described in other
tissues (Wong et al., 2012) (Figure 5F). Next we investigated
the frequency of ILC2 in mice with hepatic fibrosis. We found
that linST2+ICOS+ cells were increased in livers of mice with
CCL4 induced fibrosis (Figure 5G). However, in livers of CCL4
treated Il1rl1/ mice, ILC2 amounts were lower than in WT
mice (Figure 5H). Moreover, hepatic ILC2 numbers were also
increased in S. mansoni-infected mice (Figure 5I), whereas
blockade of IL-33 by sST2 treatment reduced liver ILC2 and
RORa mRNA (Figure 5J). These findings indicate that IL-33
signaling is important for hepatic accumulation of ILC2 during
chronic liver disease. Similar numbers of hepatic ILC2 were pre-
sent in naive Il33//4get versus Il33+/+/4get mice, suggesting
that IL-33 signalingmight not be required for ILC2 survival in con-
ditions of liver homeostasis (Figure S5C). Accordingly, hepatic
overexpression of IL-25 expanded liver ILC2 in the absence of
both IL-33 and ST2 (Figures S5D and S5E). However, although
hepatic IL-25 mRNA was somewhat increased in mice with
CCL4 or infection-dependent liver fibrosis (Figure S5F), no IL-
25 protein could be detected in the sera of these mice, suggest-
ing that IL-33 rather than IL-25 is responsible for ILC2 expansion
in chronic liver diseases.
ILC2 Mediate Hepatic Fibrosis
IL-33-treated Rag1/ mice showed higher numbers of ILC2 in
their livers than WT mice (data not shown), consistent with al) or IL-13 stimulated HSC (lower panel).
d with WST-1 assay. Control: medium alone (***p < 0.001; *p < 0.05).
hemokines in supernatants were quantified by ELISA. Data are representative
3.
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Figure 4. Innate Immune Cells Promote IL-33-Dependent Fibrosis
(A) Il1rl1/ or Il1rl1+/+ BM cells were i.v. injected into irradiated C57BL/6 recipient mice. Eight weeks later, mice received mcIL-33 via HD.
(B) Representative Sirius Red stainings of livers of mice 4 weeks after treatment.
(C) Hepatic collagen content was determined by hydroxyproline quantification (n = 5 per group; **p < 0.01).
(D–F) IL-33 expression constructs were injected into C57BL/6 or Rag1/ mice. (D) Sirius Red stainings of livers of mice 4 or 8 weeks after treatment. (E) Total
collagen in livers was determined by hydroxyproline quantification (n = 5–6 mice per group; *p < 0.05). (F) Hepatic mRNAs of fibrosis-associated genes 4 weeks
after mcIL-33 treatment in mice were quantified by qPCR (n = 5 per group; **p < 0.01; *p < 0.05). Data are representative of at least two different experiments with
similar results. Scale bars represent 200 mm. Error bars indicate SEM. See also Figure S4.
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Figure 5. IL-33 Expands Liver Resident Type-2 Related ILC that Produce IL-13
(A) Flow cytometric analysis of isolated hepatic immune cell populations from naive IL-4/eGFP reporter mice or 5 days after treatment with mcIL-33 (n = 3–4 per
group; **p < 0.01).
(B) Hepatic immune cell populations of mock or mcIL-33 injected Rag1/mice were isolated and depleted from lin+ (CD5+, B220+, CD11b+, Gr1+, 7/4+, Ter119+)
cells. The expression of IL-7Ra and ST2 was analyzed by flow cytometry. Gated IL-7Ra+/ST2+ cells were further analyzed for expression of CD45, Thy1.2, CD44,
(legend continued on next page)
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Immunity
IL-33-Dependent ILC2 Mediate Hepatic Fibrosismore severe IL-33-dependent fibrotic phenotype (Figure 4D). To
directly investigate a possible link between ILC2 and liver tissue
remodeling, we performed depletion and ILC2 transfer experi-
ments. ILC2 counts can be minimized in livers of Rag1/ mice
by treatment with aThy1.2 (CD90.2) antibodies (Figure 6A).
ILC2 depletion prior to IL-33 administration strongly reduced
IL-33-dependent hepatic fibrosis (Figure 6B), although aThy1.2
treatment 2 weeks after mcIL-33 administration was less protec-
tive (Figure S6A). Moreover, aThy1.2 treatment of Rag1/mice
(Figure S6B; Figure 6C) and C57BL/6 WT mice (Figure 6D)
resulted in significantly decreased CCL4-dependent fibrosis as
evident by reduced Sirius Red staining and hydroxyproline assay
at week 4. Similarly, ILC2 depletion in chronic CCL4-dependent
fibrosis was also efficient in Rag1/ mice reconstituted with T
and B cells from Thy1.1+ mice (Figure 6E) and resulted in
decrease expression of the fibrosis-associated genes Acta1
and Timp1 (Figure 6F). Next, we adoptively transferred purified
ILC2 from Il1rl1+/+ mice into Il1rl1/ mice and treated these
mice with mcIL-33. Analysis of liver tissue 4 weeks after treat-
ment showed that ILC2 treated mice but not controls had
marked inflammatory cell infiltrations and collagen depositions.
In contrast, no such liver alterations were observed in mcIL-33
treated Il1rl1/ control mice that received no ILC2 (Figure 7A).
Similarly, ILC2 transfer into Il1rl1/ mice subjected to the TAA
model to mimic chronic hepatocellular stress clearly increased
the degree of hepatic fibrosis (Figure 7B). Moreover, in a model
of hepatic granuloma formation by intraportal vein transfer of
Schistosome eggs (Figure S7C) the size of egg induced granu-
lomas in Il1rl1/ mice was significantly increased when ILC2
were adoptively transferred (Figure 7C).
Given that Il13/ mice are largely protected from IL-33-
dependent fibrosis (Figure 3A) and that ILC2-transferred Il1rl1/
mice treated with a vector encoding a neutralizing IL-13Ra2-Fc
fusion protein developed less IL-33-dependent fibrosis (Fig-
ure S7A), we directly testedwhether ILC2 promote hepatic tissue
remodeling via IL-13 production. By transferring WT ILC2 into
Il13/ mice, we demonstrated that ILC2 even when they are
the only IL-13 secreting cell-type were sufficient to mediate
fibrosis (Figure 7D). Accordingly other ST2+ IL-13 producing lin-
eages such as basophils and mast cells were less important for
IL-33 mediated disease (Figure S5 A and S5B) and moreover
other cytokines that were reported to be produced by ILC2
such as IL-9 (Wilhelm et al., 2011) are not as critical for IL-33
dependent fibrosis as IL-13 (Figure S7B). Collectively, these
data suggest a critical role of IL-33 dependent ILC2 in promotingICOS, and Sca-1. Blue histograms represent isotype controls. Numbers of lin IL-
per group; ***p < 0.001).
(C) Hepatic immune cells from 4get/Rag1/micewere stimulated for 4 hr with PM
expression were analyzed by flow cytometry.
(D) Total liver RNA from 5 days control or mcIL-33 treated mice was isolated and
(E) Total RNA from sort-purified liver ILC2 isolated from Rag1/mice treated for
(F) Flow-cytometry -based quantification of linSca-1+ICOS+ cells in irradiated m
(G) Flow cytometry analysis of lin, eGFP+, ICOS+ cells in livers of 4get mice trea
(H) Il1rl1+/+WT or Il1rl1/mice were treated for 4 weeks with CCL4 before hepatic
linSca-1+ICOS+ cells. Data are representative of at least two different experime
(I) CD1 mice were infected with 200 S. mansoni cercaria or left uninfected. Thr
(J) CD1 mice were infected with30 S. mansoni cercaria. Four weeks later, they w
were sacrificed and liver ILC2 numbers were determined. Hepatic Rora mRNA wa
also Figure S5.
366 Immunity 39, 357–371, August 22, 2013 ª2013 Elsevier Inc.hepatic fibrosis. Results from these experiments indicate that
IL-33 is critical for hepatic accumulation of ILC2 and that ILC2,
through an IL-13-dependent mechanism, are both required
and sufficient for hepatic fibrosis.
DISCUSSION
Hepatic fibrosis develops as a consequence of chronic liver
infections, such as HBV, HCV, or Schistosomiasis, or can occur
as a result of sustainedmetabolic or biliary imbalances. Irrespec-
tive of the underlying cause, hepatic fibrosis in humans and
experimental animal models is closely associated with persistent
activation of inflammatory pathways. However, early molecular
and cellular networks that link hepatocellular stress to inflamma-
tion and subsequently to initiation and progression of liver
fibrosis remain poorly defined. Here we present compelling
evidence that IL-33—released from liver cells in the context of
hepatocellular stress—is a key mediator of hepatic fibrosis
in vivo. We show that IL-33 release from liver cells leads to acti-
vation and expansion of IL-13 producing liver-resident ILC2 and
identify a previously unrecognized role for these cells during
hepatic tissue remodeling.
We demonstrate that elevated concentrations of IL-33 protein
in the serum and liver tissue relate to the condition of hepatic
fibrosis in humans and also are observed across different mouse
models of hepatic fibrosis, which is consistent with a recent
study reporting an association of IL-33 overexpression with
hepatic fibrosis (Marvie et al., 2010). Importantly, our data pro-
vide multiple lines of evidence that intrahepatic release of IL-33
in the context of stress-dependent cellular damage is associated
with fibrogenic changes in the liver in vivo. Taken together, these
results provide a rationale for investigation of serum IL-33 as
possible noninvasive diagnostic biomarkers of chronic hepato-
cellular injury and fibrosis; such biomarkers might be valuable
in uncovering early inflammatory and fibrogenic events and
might complement existing clinical markers of hepatic fibrosis.
To address the question of whether IL-33 was not only suffi-
cient but also required for hepatic fibrosis, IL-33-deficient mice
were challenged in two different models of hepatic fibrosis:
CCL4 and BDL. In both models, IL-33-deficient animals devel-
oped significantly reduced collagen deposits compared to WT
littermates. Similar to the reduction in collagen, expression of
ECM-associated genes was diminished in IL-33-deficient mice.
Collectively, these data support the concept that IL-33 contrib-
utes to severe hepatic fibrosis in vivo.7Ra+/ST2+ cells in livers of controls or mcIL-33 injected Rag1/mice (n = 4–8
A and Ionomycin. Surface expression of Sca-1 and ICOS and intracellular IL-13
used for RORa-specific qPCR analysis.
5 days with mcIL-33 was used for RORa- and RORg-specific qPCR (*p < 0.05).
ice reconstituted with BM from WT or sg/sg mice (n = 2–4 per group).
ted for 4 weeks with CCL4.
immune cells were isolated and analyzed by flow cytometry for the presence of
nts with five mice per group with similar results.
ee weeks later, mice liver ILC2 numbers were determined by flow cytometry.
ere HD injected with an expression construct for sST2. Four weeks later, mice
s quantified by qPCR (n = 5 per group; *p < 0.05). Error bars indicate SEM. See
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Figure 6. ILC2 Are Important Mediators of
Hepatic Fibrosis
(A) Naive 4get/Rag1/ mice were treated every
other day with 200 mg aThy1.2 mAb for 6 days.
lineGFP+ICOS+ cells in livers were analyzed by
flow cytometry.
(B) 4get/Rag1/ mice were treated every 3 days
with 200 mg aThy1.2 mAb for 4 weeks. At day 6,
mice were HD injected with mcIL-33. Collagen
depositions in livers of mice were deter-
mined by Sirius Red staining (n = 5 per group;
**p < 0.01).
(C and D) Rag1/ (C) or C57BL/6 (D) mice were
treated every 3 days with 200 mg aThy1.2 or
control mAbs for 4 weeks. Starting at day 6, mice
were treated twice weekly with 0.8 ml/kg CCL4
for 4 weeks. Collagen deposits in livers of
mice were determined by Sirius Red staining (n =
5 per group; **p < 0.01). Scale bars represent
200 mm.
(E and F) Rag1/ mice were intravenously
reconstituted with 4 3 106 purified splenic T and
B cells from Thy1.1+ mice. Seven days later, mice
were treated every 3 days with 200 mg
aThy1.2 mAb for 4 weeks. Starting at day 6, mice
were treated twice weekly with 0.8 ml/kg CCL4.
Collagen deposits in livers of mice were deter-
mined by Sirius Red staining. Scale bars
represent 200 mm. Hepatic mRNAs of Acta1
and Timp1 were determined by qPCR (n =
6–7 per group; **p < 0.01;*p < 0.05). Data
represent two independent experiments with
similar results. Error bars indicate SEM. See also
Figure S6.
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IL-33-Dependent ILC2 Mediate Hepatic FibrosisTranscriptional profiling identified IL-13, a cytokine previously
described as inflammatory and fibrogenic mediator in other
organs, as one of the most prominently upregulated genes dur-
ing IL-33-mediated hepatic fibrosis. Indeed, Il13/ and Il4Ra/
mice were markedly protected from IL-33-mediated disease
suggesting that IL-33 and IL-13 constitute a profibrotic axis in
the course of the disease. This concept is further supported by
our studies demonstrating IL-33- or IL-13-dependent hepatic
activation of STAT6 in vivo and direct activation of signaling, pro-
liferation, and gene expression of HSC in vitro. A recent report
suggested that IL-13 activates STAT6 but also SMAD-family
transcription factors in rat HSC. Through this mechanism, IL-
13 bypasses requirements for profibrotic transforming growth
factor-b (TGF-b) signaling for full HSC activation (Liu et al.,Immunity 39, 357–3712011). Consistent with the murine data,
we have demonstrated elevated hepatic
protein expression of both components
of the functional IL-13 receptor, IL-4Ra
and IL-13Ra, in human liver cirrhosis
sections compared to controls. This indi-
cates increased sensitization to IL-13-
dependent signals in human fibrotic liver
disease and suggests at least partial
functional congruence of profibrotic
hepatic networks in mouse and human.
Taken together, these findings suggest ahepatic IL-33/IL-13 axis, which promotes HSC activation and
triggers a potent fibrogenic response.
A number of different cell types have been identified as can-
didates for IL-13 production after IL-33 stimulation (Liew et al.,
2010). Although other IL-13-producing cell types such as
lymphocytes, basophils, and mast cells did not contribute
profoundly, we identified in a series of in vivo experiments a
gc-dependent non-T and non-B cell lymphoid cell population
that was a strong IL-13 producer and important pathogenic
cell type in our system. These cells depend on the expression
of the transcription factor RORa and express a panel of cell sur-
face receptors characteristic of ILC2, a recently described
innate lymphocyte subset with a key role in host defense to viral
or parasitic infection (Chang et al., 2011; Kang et al., 2012; Moro, August 22, 2013 ª2013 Elsevier Inc. 367
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Figure 7. Adoptive Transfer of ILC2
Restores Hepatic Fibrosis
(A) Il1rl1/ mice were injected i.v. with 2 3 106
sorted, WT ILC2, or saline only. Twenty-four hr
later, mice were treated with mcIL-33. Hepatic
collagen content was assessed by Sirius Red
staining (n = 4 per group; ***p < 0.001).
(B) Il1rl1/ mice were injected i.v. with 2 3 106
ILC2 or saline. Subsequently, mice were treated
i.p. for 4 weeks with TAA as described in methods.
Hepatic collagen content was assessed by Sirius
Red staining (n = 5 per group; p < 0.01).
(C) Il1rl1/ mice were injected i.v. with 2 3 106
ILC2. Twenty-four hr later, mice were injected with
5,000 freshly isolated S. mansoni eggs via the
portal vein system. Four weeks later, mice were
sacrificed and granuloma formation was analyzed
in HE stained liver sections (n = 3–4 per group;
p < 0.001).
(D) Il13/mice were injected i.v. with 23 106 ILC2
from WT Balb/c mice. Twenty-four hr later, mice
were treated with mcIL-33 via HD. Collagen
depositions in livers were determined by Sirius
Red staining and hydroxyproline assay (n = 4 per
group; **p < 0.01). Scale bars represent 200 mm (A,
B, D) or 50 mm (C). Data are representative of
at least two independent experiments with similar
results. Error bars indicate SEM. See also
Figure S7.
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IL-33-Dependent ILC2 Mediate Hepatic Fibrosiset al., 2010; Neill et al., 2010; Price et al., 2010; Saenz et al.,
2010b). Reduction of ILC2 numbers by administration of a
depleting mAb to Thy1.2 correlated with reduced sensitivity to
hepatic fibrosis after HD administration of IL-33, as well as after
chronic CCL4 challenge. Moreover, adoptive transfer of ILC2
purified from livers of WT mice into IL-33 unresponsive Il1rl1/368 Immunity 39, 357–371, August 22, 2013 ª2013 Elsevier Inc.mice restored this strains’ susceptibility
to fibrosis in the different models that
we employed indicating that intrahepatic
ILC2 have a critical role in promoting
IL-33-mediated liver fibrosis in vivo. For
the first time to our knowledge this report
describes a role for ILC2 outside the
realm of host defense at mucosal sur-
faces and establishes a role of ILC2
in hepatic tissue remodeling networks
via IL-33-dependent IL-13 production.
Further studies are required to clarify
the exact role of both IL-33 and ILC2 in
normal liver physiology, although our
results indicate that IL-33 might not be
essential for survival of hepatic ILC2 in
conditions of normal liver function.
Recently, IL-33 upregulation in hepato-
cytes and a protective role of IL-33/ST2
signaling in ConA hepatitis, a model of
acute, fulminant hepatitis in humans,
has been described (Arshad et al.,
2011; Volarevic et al., 2012). Although in
another study Il33/ mice do not show
differential susceptibility to ConA hepati-tis (Oboki et al., 2010), it is tempting to speculate that IL-33
might exert a protective role in tissue repair responses following
transient injury, whereas sustained IL-33 release due to chronic
hepatocellular stress drives pathological tissue remodeling in
the liver, as demonstrated here. Consistent with this idea,
IL-33-dependent ILC2 promote early lung tissue homeostasis
Immunity
IL-33-Dependent ILC2 Mediate Hepatic Fibrosisduring acute influenza infection (Monticelli et al., 2011) but also
mediated severe airway hyperreactivity and asthma (Barlow
et al., 2012; Bartemes et al., 2011; Chang et al., 2011). Thus,
ILC2 might have evolved to establish a direct link between
tissue damage responses and host defense, and some of the
stereotypical Th2-associated genes might more accurately be
viewed as dual role factors coordinating host defenses and
tissue remodeling.
Lastly, our findings validate the concept of therapeutic modu-
lation of IL-33 or IL-33-dependent ILC2 responses for treatment
of conditions that involve chronic hepatic inflammation and
fibrosis.
EXPERIMENTAL PROCEDURES
Animals and Mouse Models
C57BL/6, Balb/cJ, Rag1/, sg/sg, and Il4Ra/ (Balb/c background) mice
were obtained from Jackson Laboratory. Il13/ mice were kindly provided
by A. McKenzie. 4get/eGFP reporter (Mohrs et al., 2001) and Mcpt8Cre
(Ohnmacht et al., 2010) mice were obtained from D. Voehringer. Il33/ mice
were recently described (Louten et al., 2011). Il1rl1/ mice were originally
obtained from Shizuo Akira’s laboratory and backcrossed to the C57BL/6
background for ten generations. We used 8- to 12-week-old age- and sex-
matchedmice for experimental procedures. Chronic CCL4-dependent hepatic
fibrosis was induced by eight intraperitoneal injections of CCL4 (Merck) at
0.8ml/kg inmineral oil (Sigma). For eliciting thioacetamide (TAA), induced toxic
fibrosis TAA (Sigma) was intraperitoneally (i.p.) injected at 200 mg/kg thrice a
week for 4 weeks. In some experiments, cholestasis-dependent fibrosis was
induced by surgical ligation of the common bile duct under ketamine and
xylazine anesthesia. Sham-operated mice underwent laparotomy without
ligation. For analysis of hepatic IL-33 expression after Schistosoma infection,
mice were infected with 176–200 (high dose) or 30 (low dose) S. mansoni
cercaria larvae (Blank et al., 2010).
For generation of bonemarrowchimeras, 23 107 cells from femurs and tibias
of donor mice were intravenously (i.v.) injected into lethally irradiated (10Gy:
C57BL/6; 7.8 Gy: Balb/c) recipient mice. In some experiments, recipients
were i.p. pretreated for 24hrwith200ml clodronate liposomes todepleteKupffer
cells (vanRooijenandvanKesteren-Hendrikx, 2003).Micewere let to recover for
8 weeks followed by mcIL-33 injection into the tail veins. Animal experiments
were approved by the governments of Rheinland-Pfalz and Mittelfranken.
Liver Cell Isolation Procedures
Livers were aseptically removed from experimental mice, and nonparenchy-
mal liver cells were isolatedwith the gentleMACS device according to theman-
ufacturer’s instructions (Miltenyi Biotec). Briefly, livers were digested two times
for 30 min in Krebs-Ringer solution containing 5,000 U Collagenase IV (Sigma)
and 30,000 U/ml DNase I (Roche) in gentleMACS C tubes at 37C. Sub-
sequently, cells were passed through a 100 mm filter mesh and remaining
hepatocytes were removed by centrifugation at 20 g for 4 min.
For further purification of HSCs, pellets of nonparenchymal liver cells sus-
pended in 15% (w/v) iodixanol were overlaid with a solution containing 10%
(w/v) iodixanol and HBSS and centrifuged at 1,400 g for 20 min as described
previously (Elsharkawy et al., 2010). HSCs were collected at the interface of
the low-density barrier. Immediately after cell isolation, purity of isolated
HSC was examined by analysis of autofluorescence excitation under UV light
or by FACS for autofluorescence and negativity for CD45.
For further purification of immune cell populations, cells were suspended in
30% Percoll, underlaid with 100% Percoll, and centrifuged at 1,400 g for
20 min. Cells from the interface were collected, counted, and processed for
FACS analysis or cell culture. In some experiments, ILC2 populations were
enriched with a lineage cell depletion kit according to the manufacturer’s
instructions (Miltenyi Biotec).
Flow Cytometry
Single-cell suspensions from livers were stained with combinations of
the following fluorochrome-tagged antibodies (all from eBioscience unlessspecified otherwise): Allophycocyanin-conjugated anti-CD45 (30-F11), anti-
Sca-1 (D7), anti-Thy1.2 (53-2.1), anti-CD44 (IM7), Fluoresceinisothiocyanat-
conjugated anti-T1-ST2 (DJ8, MD Biosciences, Zuerich, Switzerland),
Phycoerythrin-conjugated anti-IL-13Ra1 (13MOKA), anti-IL-13 (eBio13A),
anti-ICOS (7E.17G9), and Brilliant Violet 421-conjugated anti IL-7Ra
(A7R34), anti-mouse lineage-cocktail (Biolegend). Samples were measured
on an LSRFortessa cell analyzer (BD Biosciences) and were analyzed with
Flowjo (Treestar).
In Vivo Depletion of ILC2
For depletion of ILC2 in mice anti-Thy1.2 monoclonal Ab (clone 30H12) from
BioXCell was used. We administered 200 mg per mouse i.p. every 3 days as
described in the figure legends.
Adoptive Transfers of Liver ILC2
Single-cell suspensions from livers of 4get/Rag1/mice treated with mcIL-33
for 5 days were enriched for lineage cells using a lineage cell depletion kit
according to the manufacturer’s instructions (Miltenyi Biotec). Cells were
stained with PE-conjugated antibodies to ICOS- and APC-conjugated anti-
bodies to Sca-1 and 4get/eGFP, and PE -and APC-positive cells were
collected with a FACSAria II cell sorter (Becton Dickinson). Sorted cells were
adoptively transferred to recipient mice by i.v. tail vein injection.
Cytokine and Chemokine Measurements
For determination of mouse and human IL-33, soluble ST2 ELISA and IL-13-
specific Duoset ELISA Kits fromR&DSystemswere used. Chemokine concen-
trations in cell culture supernatants and organ lysates were measured by a
mouse Flowcytomix kit (Ebioscience) according to manufacturer’s instruc-
tions. All studies with human material were approved by the ethics committee
of the University Hospital of Erlangen.
Cell Proliferation Assay
Isolated HSCs were stimulated with 20 ng/ml rIL-13 (R&D Systems, Wiesba-
den, Germany) for 72 hr, WST-1 proliferation reagent (Roche) was added
(1:10 dilution), followed by incubation for 4 hr at 37C. The absorbance was
measured at 450 nm.
Statistical Analysis
Student’s t tests orMann-Whitney tests were performedwith Graphpad 5 soft-
ware (Prism). p values < 0.05 with a 95% confidence interval were considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2013.07.018.
ACKNOWLEDGMENTS
The authors thank D. Freytag, C. Lindner, and A. Taut for excellent technical
assistance. We thank the Institute of Pathology, University Medical Center
Mainz (T. Hansen) for assistance and the NIAID Schistosoma Resource Center
for materials and technical support. This work was supported by the Collabo-
rative Research Center (SFB796 of the DFG to T.M., S.W., and M.F.N.), by an
ERC starting grant (PAS_241506 to D.V.), and by the Interdisciplinary Center
for Clinical Research (IZKF) and the ELAN program of the University Medical
Center of Erlangen (to S.W).
Received: February 13, 2012
Accepted: May 17, 2013
Published: August 15, 2013
REFERENCES
Arshad, M.I., Rauch, M., L’helgoualc’h, A., Julia, V., Leite-de-Moraes, M.C.,
Lucas-Clerc, C., Piquet-Pellorce, C., and Samson, M. (2011). NKT cells areImmunity 39, 357–371, August 22, 2013 ª2013 Elsevier Inc. 369
Immunity
IL-33-Dependent ILC2 Mediate Hepatic Fibrosisrequired to induce high IL-33 expression in hepatocytes during ConA-induced
acute hepatitis. Eur. J. Immunol. 41, 2341–2348.
Barlow, J.L., Bellosi, A., Hardman, C.S., Drynan, L.F., Wong, S.H.,
Cruickshank, J.P., and McKenzie, A.N. (2012). Innate IL-13-producing
nuocytes arise during allergic lung inflammation and contribute to airways
hyperreactivity. J. Allergy Clin. Immunol. 129, 191–198, e1–e4.
Bartemes, K.R., Iijima, K., Kobayashi, T., Kephart, G.M., McKenzie, A.N., and
Kita, H. (2011). IL-33-Responsive Lineage-CD25+CD44hi Lymphoid Cells
Mediate Innate Type 2 Immunity and Allergic Inflammation in the Lungs.
J. Immunol. 188, 1503–1513.
Bataller, R., and Brenner, D.A. (2005). Liver fibrosis. J. Clin. Invest. 115,
209–218.
Benyon, R.C., Iredale, J.P., Goddard, S., Winwood, P.J., and Arthur, M.J.P.
(1996). Expression of tissue inhibitor ofmetalloproteinases 1 and 2 is increased
in fibrotic human liver. Gastroenterology 110, 821–831.
Besnard, A.G., Togbe, D., Guillou, N., Erard, F., Quesniaux, V., and Ryffel, B.
(2011). IL-33-activated dendritic cells are critical for allergic airway inflamma-
tion. Eur. J. Immunol. 41, 1675–1686.
Blank, W.A., Test, M.R., Liu, S.F., Lewis, F.A., and Blanton, R.E. (2010). Long-
term genetic stability and population dynamics of laboratory strains of
Schistosoma mansoni. J. Parasitol. 96, 900–907.
Cayrol, C., and Girard, J.P. (2009). The IL-1-like cytokine IL-33 is inactivated
after maturation by caspase-1. Proc. Natl. Acad. Sci. USA 106, 9021–9026.
Chackerian, A.A., Oldham, E.R., Murphy, E.E., Schmitz, J., Pflanz, S., and
Kastelein, R.A. (2007). IL-1 receptor accessory protein and ST2 comprise
the IL-33 receptor complex. J. Immunol. 179, 2551–2555.
Chang, Y.J., Kim, H.Y., Albacker, L.A., Baumgarth, N., McKenzie, A.N., Smith,
D.E., Dekruyff, R.H., and Umetsu, D.T. (2011). Innate lymphoid cells mediate
influenza-induced airway hyper-reactivity independently of adaptive immunity.
Nat. Immunol. 12, 631–638.
Elsharkawy, A.M., Oakley, F., Lin, F., Packham, G., Mann, D.A., and Mann, J.
(2010). The NF-kappaB p50:p50:HDAC-1 repressor complex orchestrates
transcriptional inhibition of multiple pro-inflammatory genes. J. Hepatol. 53,
519–527.
Friedman, S.L. (2008). Mechanisms of hepatic fibrogenesis. Gastroenterology
134, 1655–1669.
Friedman, S.L. (2010). Evolving challenges in hepatic fibrosis. Nat Rev
Gastroenterol Hepatol 7, 425–436.
Haraldsen, G., Balogh, J., Pollheimer, J., Sponheim, J., and Ku¨chler, A.M.
(2009). Interleukin-33 - cytokine of dual function or novel alarmin? Trends
Immunol. 30, 227–233.
Hebenstreit, D., Wirnsberger, G., Horejs-Hoeck, J., and Duschl, A. (2006).
Signaling mechanisms, interaction partners, and target genes of STAT6.
Cytokine Growth Factor Rev. 17, 173–188.
Hoyler, T., Klose, C.S., Souabni, A., Turqueti-Neves, A., Pfeifer, D., Rawlins,
E.L., Voehringer, D., Busslinger, M., and Diefenbach, A. (2012). The transcrip-
tion factor GATA-3 controls cell fate and maintenance of type 2 innate
lymphoid cells. Immunity 37, 634–648.
Jin, Z., Sun, R., Wei, H., Gao, X., Chen, Y., and Tian, Z. (2011). Accelerated
liver fibrosis in hepatitis B virus transgenic mice: involvement of natural killer
T cells. Hepatology 53, 219–229.
Kang, Z., Swaidani, S., Yin, W., Wang, C., Barlow, J.L., Gulen, M.F., Bulek, K.,
Do, J.S., Aronica, M., McKenzie, A.N., et al. (2012). Epithelial cell-specific Act1
adaptor mediates interleukin-25-dependent helminth expulsion through
expansion of Lin(-)c-Kit(+) innate cell population. Immunity 36, 821–833.
Koyasu, S., and Moro, K. (2011). Innate Th2-type immune responses and the
natural helper cell, a newly identified lymphocyte population. Curr. Opin.
Allergy Clin. Immunol. 11, 109–114.
Kroeger, K.M., Sullivan, B.M., and Locksley, R.M. (2009). IL-18 and IL-33 elicit
Th2 cytokines from basophils via a MyD88- and p38alpha-dependent
pathway. J. Leukoc. Biol. 86, 769–778.
Liew, F.Y., Pitman, N.I., and McInnes, I.B. (2010). Disease-associated
functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10,
103–110.370 Immunity 39, 357–371, August 22, 2013 ª2013 Elsevier Inc.Liu, F., Song, Y.K., and Liu, D. (1999). Hydrodynamics-based transfection in
animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258–1266.
Liu, Y., Meyer, C., Mu¨ller, A., Herweck, F., Li, Q., Mu¨llenbach, R., Mertens,
P.R., Dooley, S., and Weng, H.L. (2011). IL-13 induces connective tissue
growth factor in rat hepatic stellate cells via TGF-b-independent Smad
signaling. J. Immunol. 187, 2814–2823.
Louten, J., Rankin, A.L., Li, Y., Murphy, E.E., Beaumont, M., Moon, C., Bourne,
P., McClanahan, T.K., Pflanz, S., and de Waal Malefyt, R. (2011). Endogenous
IL-33 enhances Th2 cytokine production and T-cell responses during allergic
airway inflammation. Int. Immunol. 23, 307–315.
Lu¨thi, A.U., Cullen, S.P., McNeela, E.A., Duriez, P.J., Afonina, I.S., Sheridan,
C., Brumatti, G., Taylor, R.C., Kersse, K., Vandenabeele, P., et al. (2009).
Suppression of interleukin-33 bioactivity through proteolysis by apoptotic
caspases. Immunity 31, 84–98.
Marvie, P., Lisbonne, M., L’helgoualc’h, A., Rauch, M., Turlin, B., Preisser, L.,
Bourd-Boittin, K., The´ret, N., Gascan, H., Piquet-Pellorce, C., and Samson, M.
(2010). Interleukin-33 overexpression is associated with liver fibrosis in mice
and humans. J. Cell. Mol. Med. 14(6B), 1726–1739.
Mjo¨sberg, J.M., Trifari, S., Crellin, N.K., Peters, C.P., van Drunen, C.M., Piet,
B., Fokkens, W.J., Cupedo, T., and Spits, H. (2011). Human IL-25- and IL-
33-responsive type 2 innate lymphoid cells are defined by expression of
CRTH2 and CD161. Nat. Immunol. 12, 1055–1062.
Mohrs, M., Shinkai, K., Mohrs, K., and Locksley, R.M. (2001). Analysis of type 2
immunity in vivo with a bicistronic IL-4 reporter. Immunity 15, 303–311.
Monticelli, L.A., Sonnenberg, G.F., Abt, M.C., Alenghat, T., Ziegler, C.G.,
Doering, T.A., Angelosanto, J.M., Laidlaw, B.J., Yang, C.Y., Sathaliyawala,
T., et al. (2011). Innate lymphoid cells promote lung-tissue homeostasis after
infection with influenza virus. Nat. Immunol. 12, 1045–1054.
Moro, K., Yamada, T., Tanabe, M., Takeuchi, T., Ikawa, T., Kawamoto, H.,
Furusawa, J., Ohtani, M., Fujii, H., and Koyasu, S. (2010). Innate production
of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid
cells. Nature 463, 540–544.
Neill, D.R., Wong, S.H., Bellosi, A., Flynn, R.J., Daly, M., Langford, T.K., Bucks,
C., Kane, C.M., Fallon, P.G., Pannell, R., et al. (2010). Nuocytes represent a
new innate effector leukocyte that mediates type-2 immunity. Nature 464,
1367–1370.
Oboki, K., Ohno, T., Kajiwara, N., Arae, K., Morita, H., Ishii, A., Nambu, A., Abe,
T., Kiyonari, H., Matsumoto, K., et al. (2010). IL-33 is a crucial amplifier of
innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA 107,
18581–18586.
Ohnmacht, C., Schwartz, C., Panzer, M., Schiedewitz, I., Naumann, R., and
Voehringer, D. (2010). Basophils orchestrate chronic allergic dermatitis and
protective immunity against helminths. Immunity 33, 364–374.
Palmer, G., and Gabay, C. (2011). Interleukin-33 biology with potential insights
into human diseases. Nat Rev Rheumatol 7, 321–329.
Palmer, G., Lipsky, B.P., Smithgall, M.D., Meininger, D., Siu, S., Talabot-Ayer,
D., Gabay, C., and Smith, D.E. (2008). The IL-1 receptor accessory protein
(AcP) is required for IL-33 signaling and soluble AcP enhances the ability of
soluble ST2 to inhibit IL-33. Cytokine 42, 358–364.
Price, A.E., Liang, H.E., Sullivan, B.M., Reinhardt, R.L., Eisley, C.J., Erle, D.J.,
and Locksley, R.M. (2010). Systemically dispersed innate IL-13-expressing
cells in type 2 immunity. Proc. Natl. Acad. Sci. USA 107, 11489–11494.
Rankin, A.L., Mumm, J.B., Murphy, E., Turner, S., Yu, N., McClanahan, T.K.,
Bourne, P.A., Pierce, R.H., Kastelein, R., and Pflanz, S. (2010). IL-33 induces
IL-13-dependent cutaneous fibrosis. J. Immunol. 184, 1526–1535.
Saenz, S.A., Noti, M., and Artis, D. (2010a). Innate immune cell populations
function as initiators and effectors in Th2 cytokine responses. Trends
Immunol. 31, 407–413.
Saenz, S.A., Siracusa, M.C., Perrigoue, J.G., Spencer, S.P., Urban, J.F., Jr.,
Tocker, J.E., Budelsky, A.L., Kleinschek, M.A., Kastelein, R.A., Kambayashi,
T., et al. (2010b). IL25 elicits a multipotent progenitor cell population that
promotes T(H)2 cytokine responses. Nature 464, 1362–1366.
Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K.,
Zurawski, G., Moshrefi, M., Qin, J., Li, X., et al. (2005). IL-33, an
Immunity
IL-33-Dependent ILC2 Mediate Hepatic Fibrosisinterleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2
and induces T helper type 2-associated cytokines. Immunity 23, 479–490.
Seki, E., De Minicis, S., Gwak, G.Y., Kluwe, J., Inokuchi, S., Bursill, C.A.,
Llovet, J.M., Brenner, D.A., and Schwabe, R.F. (2009). CCR1 and CCR5
promote hepatic fibrosis in mice. J. Clin. Invest. 119, 1858–1870.
Stolarski, B., Kurowska-Stolarska, M., Kewin, P., Xu, D., and Liew, F.Y. (2010).
IL-33 exacerbates eosinophil-mediated airway inflammation. J. Immunol. 185,
3472–3480.
van Rooijen, N., and van Kesteren-Hendrikx, E. (2003). ‘‘In vivo’’ depletion of
macrophages by liposome-mediated ‘‘suicide’’. Methods Enzymol. 373, 3–16.
Volarevic, V., Mitrovic, M., Milovanovic, M., Zelen, I., Nikolic, I., Mitrovic, S.,
Pejnovic, N., Arsenijevic, N., and Lukic, M.L. (2012). Protective role of IL-33/
ST2 axis in Con A-induced hepatitis. J. Hepatol. 56, 26–33.
Wasmuth, H.E., Tacke, F., and Trautwein, C. (2010). Chemokines in liver
inflammation and fibrosis. Semin. Liver Dis. 30, 215–225.
Weiler-Normann, C., Herkel, J., and Lohse, A.W. (2007). Mouse models of liver
fibrosis. Z. Gastroenterol. 45, 43–50.Wilhelm, C., Hirota, K., Stieglitz, B., Van Snick, J., Tolaini, M., Lahl, K.,
Sparwasser, T., Helmby, H., and Stockinger, B. (2011). An IL-9 fate reporter
demonstrates the induction of an innate IL-9 response in lung inflammation.
Nat. Immunol. 12, 1071–1077.
Wills-Karp, M., and Finkelman, F.D. (2008). Untangling the Complex Web of
IL-4-and IL-13-Mediated Signaling Pathways. Sci. Signal. 25, 1.
Wong, S.H., Walker, J.A., Jolin, H.E., Drynan, L.F., Hams, E., Camelo, A.,
Barlow, J.L., Neill, D.R., Panova, V., Koch, U., et al. (2012). Transcription factor
RORa is critical for nuocyte development. Nat. Immunol. 13, 229–236.
Xu, D., Jiang, H.R., Kewin, P., Li, Y., Mu, R., Fraser, A.R., Pitman, N.,
Kurowska-Stolarska, M., McKenzie, A.N., McInnes, I.B., and Liew, F.Y.
(2008). IL-33 exacerbates antigen-induced arthritis by activating mast cells.
Proc. Natl. Acad. Sci. USA 105, 10913–10918.
Yanaba, K., Yoshizaki, A., Asano, Y., Kadono, T., and Sato, S. (2011). Serum
IL-33 levels are raised in patients with systemic sclerosis: association with
extent of skin sclerosis and severity of pulmonary fibrosis. Clin. Rheumatol.
30, 825–830.Immunity 39, 357–371, August 22, 2013 ª2013 Elsevier Inc. 371
